Psilocybin, the psychoactive compound in “magic mushrooms,” shows early but genuine promise for reducing OCD symptoms. In the most recent clinical study, a single dose produced a moderate to large reduction in compulsive behaviors within 24 hours, with effects lasting about one week. The research is still small-scale, though, and psilocybin is not an approved treatment for OCD anywhere in the world.
What the Clinical Evidence Shows
Only a handful of studies have tested psilocybin specifically for OCD, but the results so far are striking. An early pilot study found that participants experienced 23 to 100 percent reductions in OCD symptom scores within 24 hours of a single dose, well beyond the window when the drug is still active in the body. One participant in that study maintained full symptom remission at a six-month follow-up.
A more recent study published in Comprehensive Psychiatry tested 18 adults (ages 20 to 60) with OCD, comparing a meaningful dose of 10 mg psilocybin against a very low 1 mg dose. One week after dosing, the higher dose produced a statistically significant improvement, with a large effect size. The benefit was especially pronounced for compulsions (the repetitive behaviors) rather than obsessions (the intrusive thoughts). However, the effect faded over the following three weeks.
These are small studies without the large, randomized, placebo-controlled designs that would be needed to confirm psilocybin as a reliable OCD treatment. Several larger trials are now underway, including a phase 2 study testing two 25 mg doses given two weeks apart in people with treatment-resistant OCD, and a double-blind trial at Yale.
Why Psilocybin Might Work for OCD
OCD involves rigid, self-reinforcing loops: a triggering situation produces an intrusive thought, which produces anxiety, which drives a compulsive behavior to relieve that anxiety. Over time, these loops become deeply ingrained neural habits. Standard treatments like SSRIs and cognitive behavioral therapy work in part by gradually weakening those loops, but for roughly 30 to 40 percent of people with OCD, first-line treatments don’t provide adequate relief.
Psilocybin appears to disrupt these patterns through a different mechanism. It binds strongly to serotonin receptors in the brain and triggers a temporary increase in connectivity between brain networks that don’t normally communicate much. This surge in cross-network activity is thought to loosen rigid thought patterns and make the brain more flexible, a property researchers call neuroplasticity. Think of it as temporarily softening hardened mental grooves so new, healthier patterns can form.
One influential theory, called the REBUS model, suggests that psychedelics increase the brain’s sensitivity to new information while reducing the dominance of deeply held, automatic beliefs. For someone with OCD, that could mean the brain becomes less locked into its usual cycle of obsession and compulsion, creating a window where therapeutic change is more possible. This may also explain why researchers pair psilocybin with psychotherapy in most trial designs: the drug opens a window, and the therapy helps build new patterns during that window.
The SSRI Complication
Most people being treated for OCD take an SSRI, and this creates a real practical problem. Clinical trials typically require participants to stop their SSRI at least two weeks before receiving psilocybin, for two reasons. First, SSRIs appear to significantly blunt psilocybin’s effects. Studies have found that people on SSRIs for more than three weeks report a dramatically reduced psychedelic experience, sometimes near-total elimination of the drug’s subjective effects. Second, the safety of combining the two has not been firmly established.
But stopping an SSRI carries its own risks. Discontinuation symptoms (dizziness, irritability, “brain zaps,” worsened anxiety) can be significant, and at least one research group has found that these withdrawal effects actually worsened outcomes in their trial. This is a genuine catch-22 that researchers are still working to resolve, and it’s one reason psilocybin for OCD isn’t as simple as “take a mushroom and feel better.”
How Long Relief Lasts
This is the honest weak point in the current data. The most rigorous study to date found that a single 10 mg dose produced meaningful symptom relief for about one week before the effect began to fade. The earlier pilot study reported more durable results for some participants, including one person in full remission at six months, but that study was very small and uncontrolled.
Ongoing trials are testing whether repeated doses might extend the benefit. The current phase 2 protocol for treatment-resistant OCD uses two 25 mg sessions spaced two weeks apart, combined with psychotherapy. Whether this produces longer-lasting relief remains an open question.
Who Would (and Wouldn’t) Be Eligible
Current clinical trials give a clear picture of who researchers consider safe candidates for psilocybin therapy. The exclusion list is long. You would not be eligible if you have a personal or family history of schizophrenia, bipolar disorder, or other psychotic disorders. Active suicidal thoughts, pregnancy, current substance abuse, a seizure history, or a significant head injury also disqualify participants. Anyone who has used psychedelic drugs in the past 12 months is excluded as well.
These restrictions exist because psilocybin produces a powerful altered state of consciousness, and in people predisposed to psychotic or manic episodes, that state could trigger a serious psychiatric crisis. The drug itself appears well tolerated in screened participants. Both dosages in the Yale-affiliated study produced few side effects and no serious adverse events.
Where Things Stand Now
Psilocybin for OCD is in early-stage clinical trials, mostly phase 2. It has not received FDA breakthrough therapy designation for OCD (it has for treatment-resistant depression, a related but separate path). No psilocybin-based treatment is legally available for OCD outside of clinical trials in most countries, though a few jurisdictions have begun allowing supervised psychedelic therapy for limited conditions.
The signal from early research is genuinely encouraging: rapid symptom reduction, particularly for compulsions, with a strong safety profile in carefully screened individuals. But the effects appear short-lived from a single dose, the sample sizes are tiny, and the interaction with SSRIs remains a significant hurdle. For someone with OCD exploring all options, psilocybin is worth watching closely, but it’s not yet something you can walk into a clinic and receive as a standard treatment.